Evidence map›Paper›PMID 29452121›Full record

Trial reportThe Journal of investigative dermatology2018

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.

A Jabbari, F Sansaricq, J Cerise, J C Chen, A Bitterman, G Ulerio, J Borbon, R Clynes, A M Christiano, J Mackay-Wiggan

Registry-linked trialOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of investigative dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02299297 (An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis), which is not on this map. Cited by 90 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 6 pooled it
20.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02299297 phase2completednot on this map

An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis

TypeinterventionalSponsorColumbia UniversityRan2015 to 2017Enrolled12ConditionsAlopecia AreataArmsTofacitinib
3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 6 syntheses or guidelines pooled it, 178 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Alopecia areata.Nature reviews. Disease primers · 2025
    Review
  18. Article
  19. Review
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

A JabbariDepartment of Dermatology, Columbia University, New York, New York, USA; Department of Dermatology and Interdisciplinary Program in Immunology, University of Iowa, Iowa City, Iowa, USA.
F SansaricqDepartment of Dermatology, Columbia University, New York, New York, USA.
J CeriseDepartment of Dermatology, Columbia University, New York, New York, USA.
J C ChenDepartment of Dermatology, Columbia University, New York, New York, USA.
A BittermanDepartment of Dermatology, Columbia University, New York, New York, USA.
G UlerioDepartment of Dermatology, Columbia University, New York, New York, USA.
J BorbonDepartment of Dermatology, Columbia University, New York, New York, USA.
R ClynesDepartment of Dermatology, Columbia University, New York, New York, USA; Department of Genetics, Columbia University, New York, New York, USA; Department of Pathology, Columbia University, New York, New York, USA; Department of Medicine, Columbia University, New York, New York, USA.
A M ChristianoDepartment of Dermatology, Columbia University, New York, New York, USA.
J Mackay-WigganDepartment of Dermatology, Columbia University, New York, New York, USA. Electronic address: jc299@columbia.edu.
Columbia University · USUniversity of Iowa · US

Funding

Project 1: Translational Science of Alopecia AreataP50AR070588 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHRISTIANO, ANGELA M · 2016 to 2021
$8.0M
Understanding the Biology of Chronic Ulcers: Histological and Molecular Basis...P30AR044535 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BICKERS, DAVID RINSEY · 1997 to 2015
$6.9M
Defining T helper cell associated cytokines and mechanisms in Alopecia AreataK08AR069111 · NIAMS · UNIVERSITY OF IOWA · PI JABBARI, ALI · 2016 to 2020
$854k
NIAMS NIH HHS K08 AR069111NIAMS NIH HHS P30 AR044535NIAMS NIH HHS P50 AR070588
6 · The paper itself

Abstract

Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of ∼2%. In AA, the immune system targets the hair follicle, resulting in clinical hair loss. The prognosis of AA is unpredictable, and currently there is no definitive treatment. Our previous whole genome expression studies identified active immune circuits in AA lesions, including common γ-chain cytokine and IFN pathways. Because these pathways are mediated through JAK kinases, we prioritized clinical exploration of small molecule JAK inhibitors. In preclinical trials in mice, tofacitinib successfully prevented AA development and reversed established disease. In our tofacitinib trial in 12 patients with moderate to severe AA, 11 patients completed a full course of treatment with minimal adverse events. Following limited response to the initial dose (5 mg b.i.d.), the dose was escalated (10 mg b.i.d.) for nonresponding subjects. Eight of 12 patients demonstrated ≥50% hair regrowth, while three patients demonstrated <50% hair regrowth, as measured by Severity in Alopecia Tool scoring. One patient demonstrated no regrowth. Gene expression profiles and Alopecia Areata Disease Activity Index scores correlated with clinical response. Our open-label studies of ruxolitinib and tofacitinib have shown dramatic clinical responses in moderate to severe AA, providing strong rationale for larger clinical trials using JAK inhibitors in AA. ClinicalTrials.gov ID NCT02299297.

Indexed as

AdultAlopecia AreataAutoimmune DiseasesBiopsyDose-Response Relationship, DrugFemaleGene Expression ProfilingHair FollicleHumansJanus Kinase InhibitorsJanus KinasesMaleMiddle AgedNitrilesPhotographyPilot ProjectsJanus Kinase InhibitorsJanus KinasesNitrilesPiperidinesPyrazolesPyrimidinesPyrrolesruxolitinibtofacitinib

Identifiers

PMID29452121
PMCPMC6564681
OpenAlexW2785664987

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.